Medical Crossfire®: Where CAR T and Bispecific Antibodies Fit in Lymphoid Malignancies Today… and Tomorrow

Activity Overview

The management of lymphoid malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and multiple myeloma, has been transformed by the rapid expansion of T-cell–engaging therapies. An ever-growing portfolio of FDA-approved and investigational CD19- and B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapies, alongside an increasingly competitive array of bispecific antibodies, has introduced complex decisions around treatment selection, sequencing, and safety management as these therapies move earlier into treatment paradigms.

This satellite symposium brings together expert faculty to debate the role of CAR T and bispecific antibodies in the current and future treatment of lymphoid malignancies. Presented in the Medical Crossfire® format, the program uses case-based panel discussions to address key controversies in therapy selection and sequencing, real-world feasibility vs trial outcomes, and the comparative management of CAR T– and bispecific-related toxicities.

This educational activity is an archive of the live virtual symposium held on September 10, 2026.

Target Audience

This educational activity is directed toward hematologists/oncologists, transplant physicians, advanced practice providers, nurses, and other health care providers involved in the diagnosis and treatment of hematological malignancies.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Analyze efficacy and safety data from pivotal and emerging clinical trials of CAR T-cell therapies and bispecific antibodies in lymphoid malignancies
• Integrate trial evidence with patient- and disease-specific factors to guide selection, sequencing, and timing of CAR T-cell therapies and bispecific antibodies in clinical practice
• Apply evidence-based monitoring, prevention, and multidisciplinary management strategies to mitigate acute and cumulative toxicities associated with CAR T-cell therapies and bispecific antibodies

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible companies.

PER^® mitigated all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This accredited continuing education activity was planned in accordance with the ACCME Standards for Integrity and Independence to ensure balance, objectivity, independence, and scientific rigor. Faculty were instructed to use generic names when possible and to base recommendations on the best available evidence. Proprietary product names may be referenced in clinical discussion for educational purposes only and do not imply endorsement.

This activity may include discussion of investigational, unapproved, or off‑label uses of drugs or devices. Learners are advised to consult prescribing information for products discussed. Content is provided for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Learners are encouraged to critically evaluate the information presented and apply their own clinical judgment.

The views expressed are those of the individual faculty members and do not necessarily reflect the views of the accredited provider or any entity providing commercial support.

This activity may have used AI-assisted tools to support educational development. All content was reviewed and approved by qualified faculty or planners. The accredited provider retains full responsibility for accuracy, balance, and independence.